34 completed, 8 terminated, 5 recruiting, 2 active not recruiting. 50 Phase 1, 12 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 50 | Completed 34, Terminated 8, Recruiting 5, Active not recruiting 2, Withdrawn 1 |
| Phase 2 | 12 | Completed 6, Recruiting 3, Terminated 2, Withdrawn 1 |
Follow Sarcoma, Kaposi: new trials by email Literature Review of Sarcoma, Kaposi trials Research Report on Sarcoma, Kaposi
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Sequential Infusion of CD146-Targeted and HER2-Targeted CAR T Cells in Patients With Advanced Sarcomas CD146/HER2 CAR-T cells - Sarcoma, Sarcoma, Kaposi | Phase 1 / Phase 2 | Recruiting | Essen Biotech | 60 | 2025-05-29 | 2025-07-15 |
| A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer MQ719, Pembrolizumab - Cutaneous Squamous Cell Carcinoma, SCC - Squamous Cell Carcinoma | Phase 1 | Recruiting | Memorial Sloan Kettering Cancer Center | 56 | 2023-05-04 | 2026-08-12 |
| NT-I7 for Kaposi Sarcoma in Patients With or Without HIV Efineptakin alfa - AIDS-Related Kaposi Sarcoma, HIV Infection | Phase 1 | Terminated | Fred Hutchinson Cancer Center | 8 | 2022-05-23 | 2024-06-27 |
| Pomalidomide and Nivolumab in People With Virus-Associated Malignancies With or Without HIV Pomalidomide, Nivolumab - Viral Associated Malignancies, Kaposi Sarcoma | Phase 1 | Recruiting | National Cancer Institute (NCI) | 58 | 2021-12-10 | 2026-10-16 |
| Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV Biospecimen Collection, Cabozantinib S-malate, Computed Tomography - Advanced Differentiated Thyroid Gland Carcinoma, Advanced Head and Neck Carcinoma | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 8 | 2021-11-22 | 2026-05-28 |
| Abemaciclib in Patients With HIV-associated and HIV-negative Kaposi Sarcoma Abemaciclib - Kaposi Sarcoma | Phase 1 / Phase 2 | Recruiting | National Cancer Institute (NCI) | 111 | 2021-09-29 | 2026-10-16 |
| PDS01ADC Monotherapy and in Combination With M7824 in Advanced Kaposi Sarcoma PDS01ADC, M7824 - Kaposi Sarcoma | Phase 1 / Phase 2 | Recruiting | National Cancer Institute (NCI) | 80 | 2020-07-13 | 2026-10-16 |
| An Evaluation of Tc 99m Tilmanocept by Intravenous (IV) and Subcutaneous (SC) Injection in Kaposi Sarcoma (KS) Tc99m-tilmanocept - Kaposi Sarcoma, HIV Infections | Phase 1 | Completed | Navidea Biopharmaceuticals | 15 | 2017-12-01 | 2025-03-05 |
| Testing the Addition of an Experimental Medication MK-3475 (Pembrolizumab) to Usual Anti-Retroviral Medications in Patients With HIV and Cancer Antiretroviral Therapy, Biopsy, Biospecimen Collection - AIDS-Related Non-Hodgkin Lymphoma, Clinical Stage III Cutaneous Melanoma AJCC v8 | Phase 1 | Completed | National Cancer Institute (NCI) | 58 | 2016-04-04 | 2024-08-09 |
| Pomalidomide in Combination With Liposomal Doxorubicin in People With Advanced or Refractory Kaposi Sarcoma liposomal doxorubicin, pomalidomide - Kaposi Sarcoma | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 62 | 2016-01-13 | 2026-08-28 |
| Nivolumab and Ipilimumab in Treating Patients With HIV Associated Relapsed or Refractory Classical Hodgkin Lymphoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography - Advanced Malignant Solid Neoplasm, Anal Carcinoma | Phase 1 | Terminated | National Cancer Institute (NCI) | 79 | 2015-10-21 | 2026-01-21 |
| Early Phase Evaluation of ABC294640 in Patients With Refractory/Relapsed Diffuse Large B-cell Lymphoma or Kaposi Sarcoma ABC294640 - Diffuse Large B Cell Lymphoma, Kaposi Sarcoma | Phase 1 / Phase 2 | Withdrawn | RedHill Biopharma Limited | 2014-07-01 | 2017-12-07 | |
| A Study of Selumetinib in Patients With Kaposi's Sarcoma Selumetinib - AIDS-related Kaposi's Sarcoma | Phase 1 / Phase 2 | Terminated | Sheffield Teaching Hospitals NHS Foundation Trust | 19 | 2012-06-15 | 2019-02-20 |
| Pomalidomide for Kaposi Sarcoma in People With or Without HIV Pomalidomide - Kaposi Sarcoma, Sarcoma, Kaposi | Phase 1 / Phase 2 | Completed | National Cancer Institute (NCI) | 28 | 2012-01-10 | 2022-11-01 |
| Lenalidomide in Treating Patients With AIDS-Associated Kaposi's Sarcoma Lenalidomide - AIDS-Related Kaposi Sarcoma, Recurrent Kaposi Sarcoma | Phase 1 / Phase 2 | Completed | National Cancer Institute (NCI) | 38 | 2010-08-27 | 2022-02-08 |
| Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma Gamma-Secretase Inhibitor RO4929097, Laboratory Biomarker Analysis, Pharmacological Study - Adult Alveolar Soft Part Sarcoma, Adult Angiosarcoma | Phase 1 / Phase 2 | Completed | National Cancer Institute (NCI) | 78 | 2010-06-01 | 2018-08-15 |
| Bortezomib in Treating Patients With Relapsed or Refractory AIDS-Related Kaposi Sarcoma Bortezomib, Laboratory Biomarker Analysis, Questionnaire Administration - AIDS-Related Kaposi Sarcoma, HIV Infection | Phase 1 | Completed | National Cancer Institute (NCI) | 24 | 2010-01-22 | 2018-02-20 |
| PTC299 in Treating Patients With HIV-Related Kaposi Sarcoma VEGF inhibitor PTC299, gene expression analysis, polymerase chain reaction - Kaposi's Sarcoma | Phase 1 / Phase 2 | Terminated | AIDS Malignancy Consortium | 17 | 2008-09-01 | 2018-06-06 |
| Liposomal Daunorubicin in Treating Patients With HIV-Related Kaposi's Sarcoma liposomal daunorubicin citrate - Sarcoma | Phase 1 | Terminated | AIDS Malignancy Consortium | 14 | 2008-09-01 | 2015-04-29 |
| Sirolimus in Treating Patients With HIV-Related Kaposi's Sarcoma sirolimus - Sarcoma | Phase 1 | Completed | AIDS Malignancy Consortium | 7 | 2007-10-01 | 2014-08-29 |
Showing 20 of 50. Sign in to see all of them.
HIV Infections (25) · Acquired Immunodeficiency Syndrome (24) · AIDS-related Kaposi sarcoma (17) · Sarcoma (14) · Neoplasms (9) · Melanoma (6) · Breast Neoplasms (5) · Carcinoma, Non-Small-Cell Lung (5) · Lung Neoplasms (5) · Lymphoma, Non-Hodgkin (5) · Neoplasm Metastasis (5) · Osteosarcoma (5) · Skin Neoplasms (5) · Squamous Cell Carcinoma of Head and Neck (5)
DNA Virus Infections (50) · Herpesviridae Infections (50) · Infections (50) · Neoplasms by Histologic Type (50) · Neoplasms, Connective and Soft Tissue (50) · Neoplasms, Vascular Tissue (50) · Virus Diseases (50) · Neoplasms (41) · Immune System Diseases (39) · Sarcoma (36) · Urogenital Diseases (36) · Genital Diseases (35) · Blood-Borne Infections (32) · Communicable Diseases (32) · Immunologic Deficiency Syndromes (32)
Zidovudine (6) · tecogalan (4) · Biopsy (3) · Bleomycin (3) · Doxorubicin (3) · Interferon alpha-2 (3) · Magnetic Resonance Spectroscopy (3) · Nivolumab (3) · Specimen Handling (3) · Vincristine (3) · pomalidomide (3) · Docetaxel (2) · Etoposide (2) · interferon alfa-n1 (2) · liposomal doxorubicin (2)
National Cancer Institute (NCI) (15) · National Institute of Allergy and Infectious Diseases (NIAID) (10) · Daiichi Pharmaceuticals (4) · AIDS Malignancy Consortium (3) · Case Comprehensive Cancer Center (2) · Memorial Sloan Kettering Cancer Center (2) · DEKK-TEC, Inc. (1) · Dartmouth-Hitchcock Medical Center (1) · Essen Biotech (1) · Fred Hutchinson Cancer Center (1) · National Human Genome Research Institute (NHGRI) (1) · National Institutes of Health Clinical Center (CC) (1) · Navidea Biopharmaceuticals (1) · Pfizer (1) · RedHill Biopharma Limited (1)
United States (48) · Australia (1) · Brazil (1) · China (1) · United Kingdom (1)
Ramya M Ramaswami, M.D. (4) · Gill PS (3) · Dirk Dittmer, PhD (2) · Miles S (2) · Robert Yarchoan, M.D. (2) · S Miles (2) · Scot C. Remick, MD (2) · Susan E. Krown, MD (2) · Alison L. Hannah, MBBS (1) · Amy P Sing, MD (1) · Barbara J. Klencke, MD (1) · Dezube B (1) · Diana Ritchie, Dr. (1) · Erin Reid (1)
PMID 18079362, PMID 18224669, PMID 18470481, PMID 20407240, PMID 27863194, PMID 27866590, PMID 28341759, PMID 31154457, PMID 33677480, PMID 34862247, PMID 35080914, PMID 35247913, PMID 37352498, PMID 37962072, PMID 39356983, PMID 39915263, PMID 41680482, PMID 42847673
U01CA121947 (4), P30CA043703 (2), U01CA070019 (2), UM1CA121947 (2), N01CM62206 (1), P30CA008748 (1), P30CA015704 (1), P30CA023108 (1), R44CA192859 (1), U01CA062502 (1), U01CA069856 (1), U01CA154967 (1), UM1CA154967 (1)